Articles tagged with Tay Sachs Disease
Researchers at Stanford Medicine developed a way to replace more than half of the most severely affected brain cells with non-genetically matched precursor cells in mice. The approach helped animals live longer and reduced behavioral symptoms of the disease, offering hope for families of children with these rare diseases.
Researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs diseases, two rare lysosomal storage disorders that cause progressive damage to nerve cells. The FDA-approved drug 4-phenylbutyric acid (4-PBA) showed significant improvements in motor function, lifespan, and healthy motor neurons.
A recent study by the Wellcome Sanger Institute and GeneDx analyzed nearly 30,000 families with developmental disorders, revealing that known genes explain over 80% of cases caused by recessive genetic variants. The team identified several new genes associated with these conditions, providing answers for previously undiagnosed families...
Researchers at Brigham and Women's Hospital identified ganglioside GM2 activator (GM2A) as a protein that may contribute to Alzheimer's disease progression. The protein reduces neuronal firing and induces loss of neurite integrity, suggesting its potential role in AD pathogenesis.
A new study investigates the effects of cord blood cell transplantation and curcumin administration on Tay-Sachs disease. The results show an increase in enzyme production and a decrease in inflammation after transplantation, as well as improved symptoms and reduced GM2 ganglioside levels when combined with curcumin.
Researchers have developed a gene therapy approach to treat GM2 gangliosidosis, a devastating neurodegenerative disease. The treatment has shown promising results in mouse models and is now being tested in clinical trials using recombinant Adeno-associated viruses for gene transfer.
Researchers at McMaster University have discovered that removing a key protein can significantly improve the lifespan and neurological function of mice with Tay-Sachs disease. The findings suggest that FDA-approved drugs, readily available on the market, may help alleviate symptoms of the devastating condition.
Dr. Sena-Esteves is investigating gene therapy techniques to replace the faulty gene causing Tay-Sachs Disease, a devastating neurological disorder. He's part of the Tay-Sachs Gene Therapy Consortium aiming to translate current results into a human clinical trial within three years.
A $3.5-million NIH grant will help advance a gene therapy for Tay-Sachs disease from animal tests to human clinical trials. The Boston-based consortium has successfully paired two genes in a single vector, which they believe will increase therapeutic efficiency and lower production costs.
A new screening technique using tandem mass spectrometry can detect seven devastating diseases with enzyme deficiencies in lysosomes. Early diagnosis enables the administration of treatments to repair the biochemical chain and minimize damage, offering improved quality of life for affected children.